Hwabao WP CSI Medical Service ETF(512170) Rises 2.24% in Early Trading; WuXi Family Discloses Strong Performance

NewTimeSpace News: As of 10:46 on March 24, 2026, Healthcare ETF (512170) rose 2.24%, with the latest price at 0.32 yuan. (The stocks listed above are index constituents only, with no specific recommendation intended.)

In terms of liquidity, Healthcare ETF recorded an intraday turnover rate of 1.49%, with trading volume reaching 403 million yuan. Looking at a longer time frame, as of March 23, the ETF's average daily trading volume over the past week was 778 million yuan, ranking first among comparable funds. (Data source: Wind)

In terms of scale, Healthcare ETF's assets under management grew by 1.037 billion yuan over the past three months, achieving significant growth, with the new scale ranking 1st out of 4 comparable funds. (Data source: Wind)

In terms of shares, Healthcare ETF's latest share count reached 85.686 billion shares, hitting a new high for the past year, and ranking 1st out of 4 comparable funds. (Data source: Wind)

Regarding net capital inflows, Healthcare ETF has recorded consecutive net capital inflows for 8 days, with a single-day high of 568 million yuan in net inflows, totaling 1.482 billion yuan in "capital attraction," with an average daily net inflow of 185 million yuan. (Data source: Wind)

Data shows that leveraged funds continue to build positions. Healthcare ETF has recorded net margin purchases for 6 consecutive days, with a single-day high of 111 million yuan in net purchases, with the latest margin balance at 1.269 billion yuan. (Data source: Wind)

In terms of return capability, as of March 23, 2026, since its inception, Healthcare ETF's highest monthly return was 29.81%, the longest consecutive rising period was 6 months, the longest consecutive rising gain was 26.58%, and the average return rate during rising months was 6.80%. As of March 23, 2026, Healthcare ETF's annualized excess return over the benchmark since inception was 1.68%.

In terms of drawdown, as of March 23, 2026, Healthcare ETF's relative benchmark drawdown year-to-date was 0.12%.

In terms of fees, Healthcare ETF has a management fee of 0.50% and a custody fee of 0.10%.

In terms of tracking accuracy, as of March 23, 2026, Healthcare ETF's tracking error over the past five years was 0.038%, demonstrating the highest tracking precision among comparable funds.

From a valuation perspective, the CSI Healthcare Index tracked by Healthcare ETF has a latest price-to-earnings ratio (PE-TTM) of only 29.62 times, at the 8.02nd percentile over the past year, meaning the valuation is lower than 91.98% of the time over the past year, placing it at a historical low.

Healthcare ETF closely tracks the CSI Healthcare Index. The CSI Healthcare Index selects listed company securities from the healthcare industry involved in medical devices, medical services, medical informatization, and other healthcare themes as index samples to reflect the overall performance of healthcare theme listed company securities.

Data shows that as of February 27, 2026, the top ten constituent stocks of the CSI Healthcare Index (399989) were WuXi AppTec, Mindray Medical, United Imaging, Aier Eye Hospital, Tigermed, Pharmaron, Lepu Medical, Yuwell Medical, Meinian Health, and Imeik Technology, with the top ten constituent stocks collectively accounting for 50.56%. (The stocks listed above are index constituents only, with no specific recommendation intended.)

On the news front, on the evening of March 23, WuXi family listed companies disclosed 2025 performance. In 2025, WuXi XDC achieved operating revenue of 5.944 billion yuan, a year-on-year increase of 46.7%, of which overseas revenue share climbed to 85%; adjusted net profit reached 1.559 billion yuan, a year-on-year increase of 69.9%. The group's total backlog increased to 1.49 billion US dollars, a year-on-year increase of 50.3%.

Zhongtai Securities stated that the healthcare sector is a preferred defensive base position under the "barbell strategy." Investment should focus on varieties with strong earnings certainty, and attention should be paid to reasonably valued internet leaders and pharmaceutical targets with AI transformation potential as structural opportunities for balanced allocation.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.